Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 19 Jul 2023 |
| Orion Group Half-Year Financial Report 1-6/2023 | 17 Jul 2023 |
| Orion Corporation's financial reporting and Annual General Meeting in 2024 | 17 Jul 2023 |
| Orion Corporation: Change in Orion Group Executive Management Board as of 30 April 2024 | 7 Jul 2023 |
| Orion publishes Half-Year Financial Report for January-June 2023 on Monday 17 July 2023 | 4 Jul 2023 |